Efferon develops single-use therapeutic devices for extracorporeal blood adsorption, utilizing polymeric adsorbents to selectively remove bacterial endotoxins and cytokines. This technology provides a safe and efficient method for stabilizing critically ill patients suffering from sepsis and multiple organ failure.
Funding
€2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sepsis and septic shock, often resulting from bacterial infections, lead to dangerously high levels of endotoxins and cytokines in the blood, triggering systemic inflammation and multiple organ failure. Conventional treatments may not always effectively remove these toxins, leading to high mortality rates, especially in critically ill patients.
Solution
Efferon develops single-use therapeutic devices for extracorporeal blood purification, designed to selectively remove bacterial endotoxins (LPS) and excessive inflammatory mediators like cytokines from the bloodstream. The devices contain polymeric beads, some surface-modified with LPS-selective ligands and others with anti-cytokine properties, facilitating targeted adsorption during hemoperfusion. By reducing the levels of these harmful substances, Efferon's technology aims to stabilize vital functions, reduce the duration of organ deficiency, and improve survival rates in patients with sepsis and septic shock. Clinical studies have validated the safety and efficacy of Efferon LPS in improving patient outcomes, including a reduction in the need for mechanical ventilation and a decrease in pro-inflammatory biomarkers.
Target Audience
The primary target audience includes hospitals, intensive care units, and medical professionals treating critically ill patients with sepsis, septic shock, and multiple organ failure, including both adult and pediatric populations.
Features
- Single-use cartridges for extracorporeal blood adsorption, ensuring sterility and ease of use
- Efferon LPS: Contains polymeric beads surface-modified with LPS-selective ligand for endotoxin removal
- Efferon CT: Contains anti-cytokine polymeric beads for cytokine removal
- Hemoperfusion process allows blood to pass through the adsorbent, removing toxins and returning purified blood to the patient
- Demonstrated ability to rapidly increase mean arterial pressure (MAP) and PaO2/FiO2 ratio
- Shown to progressively decline norepinephrine doses and multiorgan deficiency
- Reduction in levels of LPS, procalcitonin, C-reactive protein, interleukin-6, creatinine, leukocytes, and neutrophils
- Efferon LPS NEO device designed specifically for pediatric patients with sepsis